ClinicalTrials.gg
CompletedNCT07266779Updated Dec 5, 2025

Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.

A Phase 1 interventional study of Ertugliflozin/Metformin film coated tablets and Segluromet film coated tablets in Type 2 Diabetes, sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
19th of 28
36 · median 83
Started
2025
the only one that year
Phase 1
8 of 28
none open now
Registered
26th of 28
by date
Lead sponsor
1 of 28
Humanis Saglık Anonim Sirketi

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is the only one that started in 2025, is one of 8 in phase 1, and was the 26th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of test product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg film coated tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Reference product (R) of Segluromet 7.5 mg/ 1000 mg film coated tablets of Merck Sharp \& Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in Healthy, adult, human Subjects Under fed Condition.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject will be selected for study participation, if they meet the following criteria:

  1. Subjects aged between 18 to 45 years (both inclusive).
  2. Subjects' weight within normal range according to normal values for (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
  3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
  4. Subjects having clinically acceptable 12-lead (ECG).
  5. Subjects having clinically acceptable chest X-Ray (PA view), if taken.
  6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
  7. Subjects having negative urine alcohol test / breath alcohol test.
  8. Non-smoker.
  9. Subjects willing to adhere to the protocol requirements and to provide written .
  10. Subject with ˃45 ml/min.
  11. For male Subjects:

    • Subjects willing to follow approved methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period
  12. For Female Subjects:

    • Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
    • for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
  13. Subjects having negative urine pregnancy test at screening and negative serum β-hCG pregnancy test on admission day of period 01 (only for female subjects).

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study, if they meet any of the following criteria:

  1. to Ertugliflozin and Metformin or related class of drugs or any of its or heparin.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
  3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
  4. Presence of alcoholism or drug abuse.
  5. History or presence of asthma, urticaria or other significant allergic reactions.
  6. History or presence of significant gastric and/or duodenal ulceration.
  7. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  8. History or presence of cancer or basal or squamous cell carcinoma.
  9. Difficulty with donating blood.
  10. Difficulty in swallowing solids dosage form like tablets or capsules.
  11. Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
  12. Major illness within past 3 months.
  13. Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
  14. Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
  15. Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
  16. Positive screening test for any one or more: , and .
  17. History or presence of significant easy bruising or bleeding.
  18. History or presence of significant recent trauma.
  19. Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
  20. History of any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis).
  21. History of Diabetic pre-coma.
  22. History of acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
  23. History of disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
  24. History of Hepatic impairment or acute alcohol intoxication.
  25. Female subjects who are currently breast feeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ertugliflozin/Metformin film coated tablets

    7.5 mg Ertugliflozin / 1000 mg Metformin

    Drug: Ertugliflozin/Metformin film coated tablets · Drug: Segluromet film coated tablets

  • Active comparator
    Segluromet film coated tablets

    7.5 mg Ertugliflozin / 1000 mg Metformin

    Drug: Ertugliflozin/Metformin film coated tablets · Drug: Segluromet film coated tablets

Interventions

  • DrugErtugliflozin/Metformin film coated tablets

    Drug pages: Ertugliflozin · Metformin

    1 tablet of 7.5 mg Ertugliflozin / 1000 mg Metformin

  • DrugSegluromet film coated tablets

    7.5 mg Ertugliflozin/ 1000 mg Metformin

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration Cmax

    Acceptance range for bioequivalence is 80.00%-125.00% for geometric least square mean ratio (T/R) and it's 90% confidence interval for Cmax

    Time frame: 72 hours

  2. Area Under the Curve from time zero to time of last measurable concentration AUC0-t

    Acceptance range for bioequivalence is 80.00%-125.00% for geometric least square mean ratio (T/R) and it's 90% confidence interval for AUC0-t.

    Time frame: 72 hours

Secondary outcomes

  1. Area Under the Curve from time zero to time infinite AUC0-∞

    Descriptive statistics

    Time frame: 72 hours

  2. Time to reach peak plasma concentration Tmax

    Descriptive statistics

    Time frame: 72 hours

  3. Plasma Elimination Half-Life t1/2

    Descriptive statistics

    Time frame: 72 hours

  4. The elimination rate constant associated with the terminal (log-linear) portion of the curve Kel

    Descriptive statistics

    Time frame: 72 hours

  5. AUC0-t/ AUC0-∞

    Descriptive statistics

    Time frame: 72 hours

07

Study locations

1 site
  • Veeda Clinical Research Limited
    Gujrat, Gujarat 384205, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2025, 0 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 5, 2025
StartActual
Aug 22, 2025
Primary completionActual
Sep 4, 2025
CompletionActual
Oct 11, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07266779
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Aug 22, 2025
Primary completion
Sep 4, 2025
Completion
Oct 11, 2025
Last update
Dec 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ertugliflozin · Metformin

Start the discussion